32908 Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices 

Controlled substance Drug code Schedule 

Trimeperidine ................................................................................................................................................................... 9646 I 

1-Methyl-4-phenyl-4-propionoxypiperidine ...................................................................................................................... 9661 I 

Tilidine ............................................................................................................................................................................. 9750 I 

Para-Fluorofentanyl ......................................................................................................................................................... 9812 I 

3-Methylfentanyl .............................................................................................................................................................. 9813 I 

Alpha-methylfentanyl ....................................................................................................................................................... 9814 I 

Acetyl-alpha-methylfentanyl ............................................................................................................................................. 9815 I 

Beta-hydroxyfentanyl ....................................................................................................................................................... 9830 I 

Beta-hydroxy-3-methylfentanyl ........................................................................................................................................ 9831 I 

Alpha-methylthiofentanyl ................................................................................................................................................. 9832 I 

3-Methylthiofentanyl ......................................................................................................................................................... 9833 I 

Thiofentanyl ..................................................................................................................................................................... 9835 I 

Methamphetamine ........................................................................................................................................................... 1105 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Amobarbital ...................................................................................................................................................................... 2125 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

Secobarbital ..................................................................................................................................................................... 2315 II 

Glutethimide ..................................................................................................................................................................... 2550 II 

Nabilone ........................................................................................................................................................................... 7379 II 

1-Phenylcyclohexylamine ................................................................................................................................................ 7460 II 

Phencyclidine ................................................................................................................................................................... 7471 II 

Phenylacetone ................................................................................................................................................................. 8501 II 

1-Piperidinocyclohexanecarbonitrile ................................................................................................................................ 8603 II 

Alphaprodine .................................................................................................................................................................... 9010 II 

Dihydrocodeine ................................................................................................................................................................ 9120 II 

Ecgonine .......................................................................................................................................................................... 9180 II 

Ethylmorphine .................................................................................................................................................................. 9190 II 

Levomethorphan .............................................................................................................................................................. 9210 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. 9273 II 

Levo-alphacetylmethadol ................................................................................................................................................. 9648 II 

Noroxymorphone ............................................................................................................................................................. 9668 II 

Racemethorphan ............................................................................................................................................................. 9732 II 

Alfentanil .......................................................................................................................................................................... 9737 II 

Remifentanil ..................................................................................................................................................................... 9739 II 

Sufentanil ......................................................................................................................................................................... 9740 II 

Carfentanil ....................................................................................................................................................................... 9743 II 

Tapentadol ....................................................................................................................................................................... 9780 II 

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards and 

distribution to their research and 

forensic customers. 

Dated: July 10, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–15139 Filed 7–13–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1121–NEW] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Approval of a 

New Collection; Comments Requested: 

National Survey of Victim Service 

Providers (NCVSP) 

AGENCY: Bureau of Justice Statistics, 

Department of Justice. 

ACTION: 60-day notice. 

SUMMARY: The Department of Justice 

(DOJ), Office of Justice Programs, 

Bureau of Justice Statistics, will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

September 14, 2018. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments 

especially on the estimated public 

burden or associated response time, 

suggestions, or need a copy of the 

proposed information collection 

instrument with instructions or 

additional information, please contact 

Barbara Oudekerk, Statistician, Bureau 

of Justice Statistics, 810 Seventh Street 

NW, Washington, DC 20531 (email: 

Barbara.a.oudekerk@usdoj.gov; 

telephone: 202–616–3904). 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the Bureau of Justice 

Statistics, including whether the 

information will have practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices 32909 

* Please note that all times in this notice are in 

Mountain Daylight Time. 

** Any portion of the closed session consisting 

solely of briefings does not fall within the Sunshine 

Act’s definition of the term ‘‘meeting’’ and, 

therefore, the requirements of the Sunshine Act do 

not apply to such portion of the closed session. 5 

U.S.C. 552b(a)(2) and (b). See also 45 CFR 1622.2 

& 1622.3. 

Overview of this information 

collection: 

(1) Type of Information Collection: 

New collection. 

(2) The Title of the Form/Collection: 

National Survey of Victim Service 

Providers 

(3) The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The form number for the collection is 

NSVSP–1 (note, there will be no hard 

copy of the NSVSP instrument, the 

survey will be completed online or over 

the phone). The applicable component 

within the Department of Justice is the 

Bureau of Justice Statistics, in the Office 

of Justice Programs. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: A sample of agencies serving 

crime victims as their primary function 

or through dedicated staff or programs 

will be asked to respond. The National 

Survey of Victim Service Providers will 

gather data on the number of victims 

served by type of crime, victim 

characteristics, types of services 

provided, criminal justice and 

community relationships, service gaps, 

and VSP staff size, turnover, and 

characteristics. BJS plans to publish 

information from the NSVSP in reports 

and reference it when responding to 

queries from the U.S. Congress, 

Executive Office of the President, the 

U.S. Supreme Court, partner federal 

agencies (e.g., Office for Victims of 

Crime), state officials, international 

organizations, researchers, students, the 

media, and others interested in criminal 

justice statistics. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: A total of 8,067 victim service 

providers will be asked to respond to 

the survey. An estimated 5% of entities 

will no longer be in business or no 

longer serving victims. For ineligible 

respondents the survey will take less 

than 5 minutes to complete. Among 

active victim service providers, the 

expected response rate is 70%. For these 

5,365 active victim service providers 

that decide to participate, it will take an 

average of 45 minutes to complete the 

survey. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: There are an estimated 4,058 

total burden hours associated with this 

collection. 

If additional information is required 

contact: Melody Braswell, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Two Constitution 

Square, 145 N Street NE, 3E.405A, 

Washington, DC 20530. 

Dated: July 10, 2018. 

Melody Braswell, 

Department Clearance Officer for PRA, U.S. 

Department of Justice. 

[FR Doc. 2018–15056 Filed 7–13–18; 8:45 am] 

BILLING CODE 4410–18–P 

LEGAL SERVICES CORPORATION 

Sunshine Act Meeting 

DATE AND TIME: The Legal Services 

Corporation’s Board of Directors and its 

six committees will meet July 25–26, 

2018. On Wednesday, July 25, the first 

meeting will commence at 3:00 p.m., 

Mountain Daylight Time (MDT), with 

the meetings thereafter commencing 

promptly upon adjournment of the 

immediately preceding meeting. On 

Thursday, July 26, the first meeting will 

commence at 9:00 a.m., (MDT), with the 

next meeting commencing promptly 

upon adjournment of the immediately 

preceding meeting. The closed session 

meeting of the Board of Directors will 

commence promptly upon adjournment 

of the open session of the Board of 

Directors meeting. 

LOCATION: The Grove Hotel, 245 South 

Capitol Blvd., Boise, Idaho 83702. 

PUBLIC OBSERVATION: Unless otherwise 

noted herein, the Board and all 

committee meetings will be open to 

public observation. Members of the 

public who are unable to attend in 

person but wish to listen to the public 

proceedings may do so by following the 

telephone call-in directions provided 

below. 

Call-In Directions for Open Sessions 

• Call toll-free number: 1–866–451– 

4981; 

• When prompted, enter the 

following numeric pass code: 

5907707348 

• Once connected to the call, your 

telephone line will be automatically 

‘‘MUTED’’. 

• To participate in the meeting during 

public comment press #6 to ‘‘UNMUTE’’ 

your telephone line, once you have 

concluded your comments please press 

*6 to ‘‘MUTE’’ your line. 

Members of the public are asked to 

keep their telephones muted to 

eliminate background noises. To avoid 

disrupting the meeting, please refrain 

from placing the call on hold if doing so 

will trigger recorded music or other 

sound. From time to time, the presiding 

Chair may solicit comments from the 

public. 

MEETING SCHEDULE

Time * 

Wednesday, July 25, 2018: 

1. Governance and Performance Review 

Committee.

3:00 p.m. 

2. Operations & Regulations Committee.

3. Audit Committee.

4. Institutional Advancement Committee.

5. Communications Subcommittee Committee.

Thursday, July 26, 2018 

1. Finance Committee ... 9:00 a.m. 

2. Delivery of Legal 

Services Committee.

3. Board of Directors.

Status of Meeting: Open, except as 

noted below. 

Board of Directors—Open, except 

that, upon a vote of the Board of 

Directors, a portion of the meeting may 

be closed to the public to hear briefings 

by management and LSC’s Inspector 

General, and to consider and act on the 

General Counsel’s report on potential 

and pending litigation involving LSC, 

and on a list of prospective funders.** 

Audit Committee—Open, except that 

the meeting may be closed to the public 

to hear a briefing on the Office of 

Compliance and Enforcement’s active 

enforcement matters.** 

Institutional Advancement 

Committee—Open, except that, upon a 

vote of the Board of Directors, the 

meeting may be closed to the public to 

consider and act on recommendation of 

new Leaders Council invitees and to 

receive a briefing on the development 

activities.** 

A verbatim written transcript will be 

made of the closed session of the Board, 

Institutional Advancement Committee, 

and Audit Committee meetings. The 

transcript of any portions of the closed 

sessions falling within the relevant 

provisions of the Government in the 

Sunshine Act, 5 U.S.C. 552b(c)(6) and 

(10), will not be available for public 

inspection. 

A copy of the General Counsel’s 

Certification that, in his opinion, the 

closing is authorized by law will be 

available upon request. 


sradovich on DSK3GMQ082PROD with NOTICES